As China’s brain-computer interface (BCI) sector evolves, various stakeholders—including policymakers, healthcare providers, and corporations—are working diligently to transform extensive research into practical clinical applications. This transition marks an exciting new phase in the industry, driven by a desire to enhance patient care through neurotechnology.
A Gathering of Minds
On April 11, 2023, the National Conference on Clinical Applications and Translation of Brain-Computer Interfaces was held in Beijing as part of the 2026 Zhongguancun Forum series. The event attracted representatives from approximately 300 medical institutions, research bodies, universities, and companies, highlighting the collaborative spirit in this burgeoning field. Notable organizations, such as Beijing Tiantan Hospital and various national neurology research centers, co-hosted the conference to facilitate knowledge exchange.
During the conference, several initiatives were announced, including the start of multi-center clinical trials for the domestically developed implanted BCI system, the “NeuCyber Matrix BMI System (Beinao-1).” Plans were also disclosed for developing industrial clusters, establishing funding mechanisms, and creating clinical data platforms. These initiatives reflect the growing policy support for BCIs, which were designated as a strategic “future industry” by the Chinese government last July.
The Challenge of Clinical Validation
As the BCI industry gains momentum, a significant shared challenge has emerged: transitioning from technological exploration to scalable, real-world applications. Many industry leaders emphasize that the hallmark of success will not be rapid innovation but the ability to demonstrate consistent clinical value.
Hao Hongwei, the deputy director of the National Engineering Research Center of Neuromodulation, underscored this point, stating that a technology must show effectiveness in specific medical conditions to establish itself as a viable industry. He noted that clinical demand is the primary driving force, asserting that without genuine clinical needs, technology cannot thrive.
With millions of patients in China suffering from conditions like Parkinson’s disease, spinal cord injuries, and strokes, the demand for neurotechnology-based interventions is substantial. Hao, who also serves as the general manager of PINS Medical, explained that BCI technologies are being gradually integrated into existing healthcare practices, allowing for a sequential approach to treatment that may start with medication and rehabilitation before advancing to non-invasive or surgical options.
Diverse Paths to Development
Interviews with conference participants revealed that companies within the BCI industry are advancing along different developmental trajectories, each at varying stages of maturity. Some organizations focus on brain function monitoring and detection, reporting successful deployments in hospitals and even inclusion in public health insurance systems.
Yang Jing, a sales representative from Yiruide, a neurotechnology firm based in Beijing, highlighted that their technologies are currently utilized for diagnosing conditions like anxiety and depression, as well as tracking rehabilitation progress. The ability to quantify recovery has made these technologies more integrated into routine clinical settings.
Conversely, some companies are researching non-invasive methods that use external stimulation techniques, such as magnetic or ultrasound signals, to influence brain activity. These options are perceived as having broader potential applications due to their lower associated risks.
Shang Honglei, founder of BZ-Visual, noted that while invasive approaches are not suitable for every patient, non-invasive techniques can be broadly applied, including to those with neurological and psychiatric disorders. Meanwhile, companies focused on implanted devices recognize that invasive BCIs are still in early clinical development, with ongoing trials and regulatory approvals required.
A Shift in Perspective
Several industry leaders pointed out that successful BCI development must start from clinical problems rather than merely technological advancements. This perspective emphasizes the need to target specific medical conditions, such as paralysis or disorders of consciousness, where the unmet needs are clearly defined.
Austrian neuroscientist Gerwin Schalk echoed this sentiment, advocating for the establishment of a cohesive system that includes standardization, proper training, and practical solutions. He cautioned against the pursuit of technical breakthroughs that do not lead to usable applications, emphasizing the importance of creating clinically and commercially viable solutions.
While optimism exists, some participants urged caution regarding expectations for rapid results. As Hao stated, “BCI is about improving function, not transforming patients overnight.” A realistic, step-by-step approach will be necessary for sustained progress.
The Road Ahead
The developments within China’s BCI sector suggest that the industry is entering a phase characterized by gradual, differentiated progress. While some applications are transitioning into routine clinical use, others remain in earlier validation stages. A common thread among these efforts is the increasing importance of demonstrating measurable clinical outcomes, which will be pivotal in shaping future growth.
With ongoing policy support and heightened clinical engagement, industry stakeholders anticipate further advancements in the coming years. As validation data accumulates and regulatory frameworks become more defined, the future of BCIs will likely be shaped not by isolated breakthroughs but by steady improvements in practical applications.
In summary, the trajectory of China’s BCI industry will require balancing innovation with clinical relevance, ensuring that technological advancements translate into real-world benefits for patients.
- The BCI industry is entering a new phase focused on clinical applications.
- A strong emphasis on clinical validation is critical for industry success.
- Different companies are pursuing diverse development paths, from non-invasive to implanted devices.
- Shifting perspectives toward addressing clinical problems can enhance BCI development.
- Continued policy support will likely drive the industry’s future growth.
Read more → en.ce.cn